1DD-LSD, also known as 1-dodecanoyl-LSD or as SYN-L-004, is an acylated derivative of lysergic acid diethylamide (LSD). In animal studies, it produces a weak head-twitch response but with 27x lower potency than LSD itself. It is being researched as a potential slow-onset, long lasting prodrug for LSD which is expected to have reduced psychoactive effects.[1][2]

Use and effects

See also: LSD § Uses, and LSD § Effects

Interactions

See also: Psychedelic drug § Interactions, and Trip killer § Serotonergic psychedelic antidotes

Chemistry

Analogues

Analogues of 1DD-LSD include ALD-52 (1A-LSD), 1P-LSD, 1B-LSD, 1H-LSD, and 1V-LSD, among others.

Society and culture

Canada

1DD-LSD is not a controlled substance in Canada as of 2025.[3]

United States

1DD-LSD is not an explicitly controlled substance in the United States.[4] However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.

See also

References

  1. ^ Kavanagh PV, Westphal F, Pulver B, Elliott SP, Stratford A, Halberstadt AL, Brandt SD (April 2024). "Analytical and behavioral characterization of 1-dodecanoyl-LSD (1DD-LSD)". Drug Testing and Analysis. 17 (1): 101–109. doi:10.1002/dta.3691. PMC 11730435. PMID 38569566.
  2. ^ WO 2024/028495, Stratford A, Williamson JP, "Prodrugs of Substituted Ergolines", published 8 February 2024, assigned to Synex Holdings BV 
  3. ^ "Controlled Drugs and Substances Act". Department of Justice Canada. Retrieved 19 January 2026.
  4. ^ Orange Book: List of Controlled Substances and Regulated Chemicals (January 2026) (PDF), United States: U.S. Department of Justice: Drug Enforcement Administration (DEA): Diversion Control Division, January 2026
source: https://en.wikipedia.org/wiki/1DD-LSD